| Followers | 0 |
| Posts | 1357 |
| Boards Moderated | 0 |
| Alias Born | 03/20/2022 |
Sunday, April 03, 2022 11:14:04 PM
Where is all this extra cash to pay patients and speed up enrollment is supposed to come from exactly?
The screening of patients based on the criteria listed looks to be time consuming and very costly.
Its not like Revive has started generating any revs yet.
Last I checked they have already burned through ~$21M in the last year, the majority of which has been for the trial....there are many other expenses to be paid and cash is limited imo.
I get that people are impatient but the fact remains we are not connected like the pfizers and modernas, meaning we dont get a pass.
We already that covid will be with us for a very long time in ever changing forms and as such time is not the "killshot" issue its being made out to be....just yet.
The other pills from pfizer and merck are not scalable yet and theyre not for general use as Bucil will be if its granted eua.
At this point the only thing that really matters is that its found to be effective, not how long the trial is taking.
AIMOOC
The screening of patients based on the criteria listed looks to be time consuming and very costly.
Its not like Revive has started generating any revs yet.
Last I checked they have already burned through ~$21M in the last year, the majority of which has been for the trial....there are many other expenses to be paid and cash is limited imo.
I get that people are impatient but the fact remains we are not connected like the pfizers and modernas, meaning we dont get a pass.
We already that covid will be with us for a very long time in ever changing forms and as such time is not the "killshot" issue its being made out to be....just yet.
The other pills from pfizer and merck are not scalable yet and theyre not for general use as Bucil will be if its granted eua.
At this point the only thing that really matters is that its found to be effective, not how long the trial is taking.
AIMOOC
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
